Novo Nordisk to cap insulin prices in Minnesota settlement
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.
Danish businesses are concerned about a possible trade conflict with the United States over Greenland, a major lobby group ...
(Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening ...
In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...
Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...
Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor agonist intended for once weekly subcutaneous administration.
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Novo Nordisk announces positive results from phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity: Bagsværd, Denmark Monday, January 27, 2025, 13:00 ...
Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other ...